(Reuters) - Wall Street dropped on Friday, and also finished the week lower, after a Chinese agriculture delegation canceled a planned visit to Montana, dampening optimism about U.S.-China trade talks.
The delegates, who had been set to visit U.S. farm states next week, will return to China sooner than originally scheduled, the Montana Farm Bureau said.
Major stock indexes fell into negative territory after the cancellation, which came as trade talks were held in Washington and U.S. President Donald Trump said he wanted a complete trade deal, not just an agreement for China to buy more U.S. agricultural goods. Before the news, the S&P 500 and Dow industrials were in positive territory.
For months, Wall Street has bounced up and down with signs of improvement or deterioration in trade talks, often based on comments or tweets from Trump, a cycle investors have grown accustomed to.
“In this case, it’s a bit more concerning because it’s China making the decision, rather than Trump,” said Willie Delwiche, markets strategist at Baird in Milwaukee.
Trade optimism in recent weeks helped elevate the S&P 500 .SPX to just shy of its all-time high hit in July.
Eight of the 11 major S&P sectors fell on Friday. The S&P 500 consumer discretionary index .SPLRCD and tariff-sensitive S&P 500 information technology index .SPLRCT declined the most, down 1.2% and 1.1%, respectively. The Philadelphia chip index .SOX slid 1.8%.
The Nasdaq Composite .IXIC dropped 0.8% to 8,117.67.
For the week, the S&P 500 fell 0.52%, the Dow lost 1.05% and the Nasdaq declined 0.72%.
Adding to Netflix’s woes, Evercore ISI said recent data painted an uncertain picture of the company’s international subscriber growth.
The S&P 500 healthcare index .SPXHC, which has been the worst performing S&P sector this year, clocked the biggest gain among the 11 major sectors, up 0.6%.
Merck & Co (MRK.N) gained 1.4% after the company’s drugs Pifeltro and Delstrigo received FDA approval for use in certain adult patients with HIV-1 who are “virally suppressed.”
Roku Inc (ROKU.O) slumped 19.2% after Pivotal Research started coverage of its shares with a “sell” rating.
Xilinx Inc (XLNX.O) dropped 6.8% after Chief Financial Officer Lorenzo Flores said he would step down, prompting Bank of America Merrill to downgrade the chipmaker to “neutral.”
Advancing issues outnumbered declining ones on the NYSE by a 1.01-to-1 ratio; on Nasdaq, a 1.03-to-1 ratio favored decliners.
The S&P 500 posted 22 new 52-week highs and no new lows; the Nasdaq Composite recorded 47 new highs and 51 new lows.
With investors unwinding positions in futures and options contracts before they expire, volume on U.S. exchanges was 9.8 billion shares, compared with a 7.1 billion-share average over the last 20 trading days.
Additional reporting by Ambar Warrick and Medha Singh in Bengaluru; Editing by Steve Orlofsky and David Gregorio